Financial insights of DNLI

MyFinsight

For the quarter ending 2026-03-31.

Income Statement	2026-03-31	2025-12-31	2025-09-30	2025-06-30
Total collaboration revenue	-	0*	-	-
Research and development	103,846	111,885*	101,950	102,696
General and administration	33,511	34,938*	35,484	32,267
Total operating expenses	137,357	146,822*	137,434	134,963
Gain from divestiture of small molecule programs	-	0*	0	0
Loss from operations	-137,357	-146,822*	-137,434	-134,963
Interest and other income, net	8,910	10,840*	10,532	10,844
Loss before income taxes	-	-135,982*	-	-
Income tax expense	-	26*	-	-
Net loss	-128,447	-136,008*	-126,902	-124,119
Net unrealized loss (gain) on marketable securities, net of tax	-1,364	66*	162	-1,098
Comprehensive loss	-129,811	-135,942	-126,740	-125,217

Basic EPS	-0.69	-0.781	-0.74	-0.72
Diluted EPS	-0.69	-0.781	-0.74	-0.72
Basic Average Shares	186,636,978	174,075,952	172,421,492	171,449,847
Diluted Average Shares	186,636,978	174,075,952	172,421,492	171,449,847

Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.